Is Regeneron Pharmaceuticals, Inc. (REGN) a good stock to buy?

Olyth's institutional analysis of REGN reveals an Altman Z-Score of 7.56 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($14.34B most recent), help investors decide if REGN fits their risk profile.

What is the current P/E ratio for REGN?

As of the latest trading session, Regeneron Pharmaceuticals, Inc. (REGN) has a trailing P/E ratio of 17.43.

Who is the CEO of Regeneron Pharmaceuticals, Inc.?

The current Chief Executive Officer of Regeneron Pharmaceuticals, Inc. is Leonard S. Schleifer.

What was REGN's revenue for the last 5 years?

According to its latest income statements, Regeneron Pharmaceuticals, Inc. reported annual revenues of $14.34B (2025), $14.20B (2024), $13.12B (2023), $12.17B (2022), $16.07B (2021) respectively.

Does REGN pay a dividend?

Regeneron Pharmaceuticals, Inc. currently pays a dividend to its shareholders, with a trailing dividend yield of 0.47%.

How much debt and cash flow does REGN have?

In its latest reporting period, Regeneron Pharmaceuticals, Inc. generated $4.08B in Free Cash Flow against a total debt load of $2.71B.

What is the Price-to-Book (P/B) ratio of Regeneron Pharmaceuticals, Inc.?

The Price-to-Book (P/B) ratio for Regeneron Pharmaceuticals, Inc. (REGN) is currently 2.51.

What is the Price-to-Sales (P/S) ratio of REGN?

Based on trailing twelve-month data, Regeneron Pharmaceuticals, Inc. (REGN) trades at a Price-to-Sales (P/S) ratio of 5.53.

What is Regeneron Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Regeneron Pharmaceuticals, Inc. (REGN) has a Return on Equity (ROE) of 14.83%, representing its profitability relative to shareholder equity.

REGN

Regeneron Pharmaceuticals, Inc. · Healthcare

763.04

0.16%(+1.19)

Prev. Close

764.32

0.17%(+1.28)

Pre-market

Last Updated: — ET

52W L: $476.4952W H: $821.11

$760.78

CHG+6.50 (+0.86%)

H$788.84

L$717.06

VOL11M

REGN (1h)

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

15,158

IPO Date

1991-04-02

Beta

0.40

Websitewww.regeneron.com↗

REGN

Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval

All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

TriNetX arbeitet mit Regeneron zusammen, um Zugang zu anonymisierten elektronischen Patientenakten von 300 Millionen Patienten zu erhalten und damit die Forschung und Produktentwicklung in den Bereichen Biowissenschaften und digitale Gesundheitslösungen voranzutreiben

TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados